AI and Cancer Research ── Colorectal ── 2026-11-20

Colorectal cancer: screening, treatment, trials and AI
- Abstract
Colorectal cancer (CRC) requires robust biomarkers and therapeutic targets. This study aimed to identify secretome-associated genes with diagnostic, prognostic, and tumor-suppressive relevance in CRC, focusing on GUCA2B (uroguanylin). We integrated single-cell transcriptomics, pseudobulk differential expression, machine learning (ML), multi-omics, and in vitro functional assays (HCT-116 cells). ML consensus feature selection across four algorithms identified 20 shared features from 850 downregulated genes; eight genes, including GUCA2B, were selected by all four models, forming the finalized signature. GUCA2B was markedly reduced in CRC epithelium. A frozen eight-gene logistic model showed an apparent (training-set) AUC of 0.998 in TCGA-COADREAD and maintained discrimination in three independent cohorts (AUC = 0.881-0.974). Reduced GUCA2B expression correlated with adverse survival, promoter hypermethylation, and altered immune infiltration. In vitro, GUCA2B restoration induced intrinsic apoptosis (increased BAX, decreased BCL2), reduced viability, and impaired migration; because GC-C/cGMP dependence was not tested, these effects constitute receptor-mechanism-agnostic proof of concept. In conclusion, GUCA2B represents a candidate epithelial-restricted CRC biomarker and tumor-suppressive gene. While the frozen multi-gene model shows promise for diagnostic stratification and GUCA2B restoration demonstrates preliminary tumor-suppressive activity, the small discovery set (n = 23 pseudobulk samples), moderate feature-selection stability, and single-cell-line validation necessitate cautious interpretation. Prospective clinical validation and in vivo multi-model studies are required before diagnostic or therapeutic application.
Journal IF-equivalent: 4.9 (OpenAlex 2-year mean citedness, value as of 2026-11-17, retrieved 2026-11-19; not the official Clarivate IF)Reference: Samadi P, Maghool F, Nouri F, Jalali A. Machine learning pipeline for secretome biomarker discovery in colorectal cancer: from single-cell transcriptomics to functional validation. Naunyn-Schmiedeberg's Arch Pharmacol. 2026 Nov 18 [Epub ahead of print]. doi:10.1007/s00210-026-06059-1.Checked: Abstract only